Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $3.35B
• Dividend Yield: N/A
• Average Volume (3M): 539.72K
• Price to Earnings (P/E): 16.0
• Beta (1Y): 0.28
• Revenue Growth: 0.63%
• EPS Growth: 4.23%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Distribution
• EPS (TTM): 0.95
• Shares Outstanding: 49,214,172
• 10 Day Avg. Volume: 594,447
• 30 Day Avg. Volume: 539,722
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.46
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 7.76
• Enterprise Value/Ebitda: 13.58
• 1Y Price Target: $85.00
• Price Target Upside: 24.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 65 Neutral
• Price Target: $70.00 ▲(2.88% Upside)

Prestige Consumer Healthcare's overall score reflects a mix of solid financial performance and strategic initiatives, tempered by current technical weaknesses and supply chain challenges. The acquisition of Pillar5 Pharma is a positive step towards addressing these issues, but the stock's technical indicators suggest caution in the short term.

Positive Factors

Brand-building and strategic growth

Management's overall strategy around brand-building and utilizing disciplined M&A to grow the business can continue to drive strong FCF and shareholder returns despite the near-term topline headwinds from the eye care business.

Debt reduction and capital allocation

Strong free cash flow enabled further debt reduction and share repurchases.

Partnerships and acquisitions

PBH has further diversified its eye care manufacturing with new third-party partnerships and the acquisition of one of its partner's facility in Canada for $100M, which is expected to help the business start to recover.

Negative Factors

Financial guidance and expectations

The company lowered its financial guidance for the year due to ongoing eye care constraints, impacting expectations.

Sales performance

A sales shortfall, caused by an inability to source enough eye care product (Clear Eyes) to meet retailer and consumer demand, was a suboptimal way to start the fiscal year.

Supply constraints

PBH reported lower-than-expected sales and earnings due to supply constraints in the eye care business, leading to a weaker performance in North America.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

How the Company Makes Money

PBH generates revenue primarily through the sale of its branded OTC healthcare products in both retail and e-commerce channels. The company leverages its established brand portfolio and extensive distribution network to reach consumers effectively. Key revenue streams include direct sales to major retail chains, pharmacies, and online platforms. Additionally, PBH benefits from partnerships with various retailers for promotional activities and shelf space, which enhance product visibility and sales. The company also invests in marketing and innovation to develop new products and improve existing ones, driving further revenue growth.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates solid financial health across income, balance sheet, and cash flow metrics. The company shows consistent revenue growth and strong profitability margins, while maintaining a low leverage position. Cash flow generation is stable, supporting operational and financial flexibility. Overall, the company's financial statements reflect a well-managed business with potential for continued growth and profitability.

Income Statement

Prestige Consumer Healthcare has shown consistent revenue growth, with a 1.1% increase from 2024 to 2025. The gross profit margin remains strong at 55.8% in 2025, reflecting effective cost management. However, the EBIT margin slightly decreased from 30.4% in 2024 to 29.6% in 2025, indicating some pressure on operational efficiency. The net profit margin improved slightly to 18.9% in 2025, highlighting enhanced profitability.

Balance Sheet

The company's financial stability is solid with a low debt-to-equity ratio of 0.03 in 2025, demonstrating effective debt management. The equity ratio is strong at 53.9%, indicating a healthy proportion of equity financing. Return on equity stands at 11.7%, showing reasonable profitability for shareholders. The improvement in equity and reduction in total liabilities over the years reflect a strengthening balance sheet.

Cash Flow

Operating cash flow increased slightly to $251.5 million in 2025, supporting ongoing operations effectively. Free cash flow growth is modest at 1.6% year-over-year, but the free cash flow to net income ratio is robust at 1.13, indicating strong cash generation relative to profits. The stable cash flow trends suggest efficient cash management and operational stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.12B	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	629.29M	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	359.60M	361.99M	373.86M	14.19M	351.61M	310.38M
Net Income	213.00M	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.43B	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	139.50M	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	1.04B	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.58B	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.86B	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	267.84M	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	275.75M	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-17.26M	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-152.84M	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 68.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Neutral. The current price of 68.04 is above the 20-day moving average (MA) of 67.18, below the 50-day MA of 73.68, and below the 200-day MA of 80.45, indicating a neutral trend. The MACD of -2.03 indicates Negative momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 91.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDCO	70 Outperform		―		―	-0.85%	-23.40%
HSIC	70 Outperform	$8.44B	22.37	11.18%	―	2.29%	14.98%
PBH	65 Neutral	$3.35B	15.96	12.05%	―	0.63%	4.23%
CAH	59 Neutral	$35.53B	23.18	-43.80%	1.36%	-1.94%	85.70%
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
GRDN	47 Neutral	$1.67B	―	-97.70%	―	―	―
OMI	43 Neutral	$378.50M	―	-144.11%	―	-17.10%	-2720.40%

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion

On August 4, 2025, Prestige Consumer Healthcare Inc. announced a definitive agreement to acquire Pillar5 Pharma Inc., a leading Canadian sterile ophthalmic manufacturer and current supplier of Clear Eyes, from ANJAC SAS for CAD 150 million. This acquisition is part of Prestige’s strategy to expand eye care production capacity and address supply chain challenges, with the transaction expected to close in the third quarter of fiscal 2026. The company also reported a decline in first-quarter fiscal 2026 revenue to $249.5 million due to supply constraints in the eye care category, although international segment growth and improved gross margins were noted. The acquisition of Pillar5 is anticipated to secure long-term supply chain capacity and support Prestige’s growth opportunities, despite a revised revenue outlook for fiscal 2026.